Tag: European union drug compliance

Ibogaine treats ADHD
The continuous evolution of neuropharmacology, treatment-resistant neurological anomalies, and alternative psychiatric interventions has challenged traditional clinical perspectives on cognitive regulation. Attention-Deficit/Hyperactivity Disorder (ADHD) has long been managed through standard psychostimulants like methylphenidate and amphetamine derivatives, alongside cognitive behavioral therapy. However, a significant subset of adults experience persistent executive dysfunction, emotional dysregulation, chronic burnout, and compulsive […]
Ibogaine treats Complex PTSD
The management of severe psychological trauma, treatment-resistant post-traumatic stress, and deeply entrenched neuro-emotional distress requires an absolute paradigm shift in clinical psychiatry. Complex Post-Traumatic Stress Disorder (C-PTSD)—arising from chronic, prolonged, or repeated interpersonal trauma—frequently resists conventional therapeutic modalities, long-term psychotherapy, and standard pharmacotherapy such as selective serotonin reuptake inhibitors. For individuals navigating these debilitating conditions […]